Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  BJU International

• Publication date

  2015-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bju.12880PMID 25060664
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Active surveillance for low-risk prostate cancer: diversity of practice across Europe

  2015cited by this paper
• Gleason Score 3 + 4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen

  2014cited by this paper
• Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.

  2014cited by this paper
• Biopsy criteria for determining appropriateness for active surveillance in the modern era.

  2014cited by this paper
• Patient selection and pathological outcomes using currently available active surveillance criteria

  2013cited by this paper
• Active surveillance: patient selection

  2013cited by this paper
• Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.

  2013cited by this paper
• Architectural Heterogeneity and Cribriform Pattern Predict Adverse Clinical Outcome for Gleason Grade 4 Prostatic Adenocarcinoma

  2013cited by this paper
• Medium-term outcomes of active surveillance for localised prostate cancer.

  2013cited by this paper
• Active surveillance for prostate cancer: past, present and future

  2012cited by this paper
• Extended biopsy based criteria incorporating cumulative cancer length for predicting clinically insignificant prostate cancer

  2012cited by this paper
• Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy.

  2012cited by this paper
• Active surveillance: the Canadian experience with an "inclusive approach".

  2012cited by this paper
• Active surveillance for prostate cancer: a systematic review of the literature.

  2012cited by this paper
• Impact on the Clinical Outcome of Prostate Cancer by the 2005 International Society of Urological Pathology Modified Gleason Grading System

  2012cited by this paper
• Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

  2011cited by this paper
• Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols.

  2010cited by this paper
• Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point

  2010cited by this paper
• The 2010 NCCN clinical practice guidelines in oncology on prostate cancer.

  2010cited by this paper
• ERG rearrangement is present in a subset of transition zone prostatic tumors

  2010cited by this paper
• Gleason score 7 screen‐detected prostate cancers initially managed expectantly: outcomes in 50 men

  2009cited by this paper
• Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.

  2007cited by this paper
• The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

  2005cited by this paper
• Early outcomes of active surveillance for localized prostate cancer

  2005cited by this paper
• An analysis of men with clinically localized prostate cancer who deferred definitive therapy.

  2004cited by this paper
• Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.

  2003cited by this paper
• Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

  1994cited by this paper

• From non-clinically significant to clinically significant prostate cancer: identifying predictors of discrepancy from biopsy to radical prostatectomy.

  2025cites this paper
• High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy

  2024cites this paper
• Development and internal validation of a novel nomogram for predicting lymph node invasion for prostate cancer patients undergoing extended pelvic lymph node dissection

  2023cites this paper
• Adverse pathology after radical prostatectomy: the prognostic role of cumulative cancer length >6-mm threshold in prostate cancer–positive biopsies

  2019cites this paper
• Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.

  2017cites this paper
• The biopsy Gleason score 3+4 in a single core does not necessarily reflect an unfavourable pathological disease after radical prostatectomy in comparison with biopsy Gleason score 3+3: looking for larger selection criteria for active surveillance candidates

  2015cites this paper